59P Real-world data of immunotherapy in patients over 65 years old with lung cancer

Immunotherapy (IO) has become one of the leading treatments for advanced lung cancer. The number of elderly patients treated in routine clinical practice contrasts with the low representation of these in clinical trials. The aim of the study is to establish clinical differences between patients older and younger than 65 years treated with IO. We conducted a single centre retrospective review including 137 patients treated with IO in Puerta de Hierro University Hospital (Madrid) between 2014 and 2019. We collected information regarding epidemiology, treatments, response and survival patterns and we performed a comparative analysis between patients <65 and ≥ 65 years. Clinical data, toxicities, treatments and survival are shown in the table. There were no differences in high grade toxicities (9.1% vs 10.4%) or treatment interruption (20.3% vs 17.6%, p=0.576). We didn´t find difference in OS (16.0 vs 17.0) between both groups. Table: 59P<65 (69)>65 (68)Long rank (p)Sex M F54.5% 45.6%74.6% 25.4%Age5872ECOG 0-1 ≥293.2% 4.5%97.0% 3.0%Histology Adenocarcinoma Squamous Small cell Others59.1% 27.3% 2.3% 11.4%56.7% 25.4% 4.5% 13.4%Toxicity type Asthenia Pneumonitis Thyroid disorders Skin Others11.4% 14.8% 10.2% 9.1% 24.9%13.4% 11.9% 11.9% 9.0% 19.5%Grade 1-2 ≥323.8% 9.1%28.3% 10.4%0.99Treatments (CI, 95%)Median OS16.0 (9.1-22.9)17.0 (7.5-26.5)0.8251° lineMedian PFS3.0 (0-6.8)7.0 (1.2-12.8)0.164Duration (median)3.03.02° lineMedian PFS11.0 (9.6-12.4)11.0 (5.1-16.9)0.837Duration (median)9.54.03° lineMedian PFS2.0 (1.2-2.8)2.0 (0.1-3.9)0.338Duration (median)2.02.0 Open table in a new tab Our results show that IO has an adequate safety profile in patients ≥65 years and survival results are similar to young patients. Therefore, in our opinion, IO represents a valid and safe option for advanced lung cancer treatment in patients ≥65 years.